Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on dosing cohorts, mTOR inhibition data, and brain-tumor trial endpoints can make Biodexa Pharmaceuticals’ SEC filings feel impenetrable. Yet those same documents hide the details that move BDRX shares—cash runway disclosures, exclusive licensing terms, and upcoming FDA milestones. When you need to trace how Tolimidone’s diabetes study affects revenue projections or confirm executive stock sales ahead of an 8-K data read-out, spending hours sifting through jargon isn’t an option.
Stock Titan solves that problem. Our AI-powered summaries translate every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event into plain English, highlighting R&D spend, pipeline updates, and risk factors. Real-time alerts flag Biodexa Pharmaceuticals insider trading Form 4 transactions the moment they hit EDGAR, while side-by-side comparisons let you track clinical progress across reporting periods. Whether you search for “Biodexa annual report 10-K simplified” or “understanding Biodexa SEC documents with AI,” you’ll land on clear explanations, not raw PDFs.
Here’s what you can explore in one place:
- Form 4 insider trades—follow Biodexa executive stock transactions Form 4 in real time.
- 10-Q filings—get concise Biodexa quarterly earnings report 10-Q filing insights on R&D burn and runway.
- 8-K updates—see pivotal trial read-outs or licensing deals, Biodexa 8-K material events explained.
- Proxy statements—review Biodexa proxy statement executive compensation without the legal maze.
From “Biodexa earnings report filing analysis” to “Biodexa SEC filings explained simply,” Stock Titan equips investors, analysts, and researchers with the information that drives confident decisions—minus the complexity.
Biodexa Pharmaceuticals (NASDAQ: BDRX) has filed a Prospectus Supplement No. 5 to incorporate information from their Form 6-K dated June 27, 2025. The filing covers the resale of 2,486,190,000 ordinary shares (representing 248,619 American Depositary Shares) by selling shareholders.
Key highlights:
- All resolutions at the Annual General Meeting held on June 26, 2025, were successfully passed
- Last reported closing price of ADSs was $0.9215 on NASDAQ Capital Market
- Company's pipeline includes three main development programs: - eRapa: For Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer - Tolimidone: For type 1 diabetes treatment - MTX110: For aggressive rare/orphan brain cancer indications
The company leverages three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of medicines, with headquarters and R&D facility in Cardiff, UK.
Biodexa Pharmaceuticals has filed a prospectus supplement related to the potential resale of 341,352,000,000 ordinary shares (representing 34,135,200 American Depositary Shares). The company's ADSs trade on NASDAQ under symbol BDRX, with a last reported closing price of $0.9215 on June 26, 2025.
The filing also includes Form 6-K reporting the results of their Annual General Meeting held on June 26, 2025, where all proposed resolutions were passed. The company is advancing several key drug development programs:
- eRapa - An oral rapamycin formulation for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer
- Tolimidone - A Lyn kinase inhibitor for type 1 diabetes treatment
- MTX110 - A panobinostat formulation for rare/orphan brain cancers
The company leverages three proprietary drug delivery technologies to improve bio-delivery and bio-distribution of medicines. Their R&D facility is located in Cardiff, UK.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) filed a Form 6-K to report the outcome of its 26 June 2025 Annual General Meeting. The company confirms that every resolution listed in the 23 May 2025 AGM notice was duly approved by shareholders. Although the filing does not enumerate the resolutions or voting percentages, management notes that the results have been incorporated by reference into its effective registration statements on Form S-8 (No. 333-209365) and Form F-3 (No. 333-267932), thereby keeping those shelf offerings current.
A related press release dated 27 June 2025 (Exhibit 99.1) reiterates the successful passage of all motions. The press release is furnished—not filed—under the Exchange Act, limiting potential liability under Section 18.
No financial statements, earnings data, or strategic transaction details were included. The disclosure is largely procedural, aimed at satisfying SEC requirements and informing investors that corporate authorisations—potentially covering director re-elections, auditor appointment, remuneration, and share-issuance mandates—remain in force.
FAQ
What is the current stock price of Biodexa Pharmaceuticals plc (BDRX)?
What is the market cap of Biodexa Pharmaceuticals plc (BDRX)?
What is the core business of Biodexa Pharmaceuticals PLC?
How does Biodexa utilize its drug delivery technology?
What are the primary therapeutic areas Biodexa is engaged in?
How does Biodexa mitigate the clinical risk associated with drug development?
What makes Biodexa's approach to drug development unique?
How does the company position itself in a competitive biopharmaceutical market?
What role does innovation play in Biodexa's business model?
How does Biodexa enhance the treatment of diseases with unmet medical needs?
